Japan’s Daiichi Sets August Dates For Offer To Buy India’s Ranbaxy
This article was originally published in PharmAsia News
Daiichi Sankyo of Japan says it plans to make its move on Ranbaxy Laboratories of India early in August when it makes its tender offer for shares. In addition to the tender offer, expected as early as Aug. 8, Daiichi plans to buy at least half of the stock owned by the founding family. The timing of the tender offer, which probably would expire Aug. 27, is subject to approval by Indian regulators, so the dates could be delayed. (Click here for more - a subscription may be required
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.